Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeSales of Property, Plant and EquipmentSales of Property, Plant and EquipmentShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zentalis Pharmaceuticals (ZNTL) Share-based Compensation (2022 - 2026)

Zentalis Pharmaceuticals has reported Share-based Compensation over the past 5 years, most recently at $3.2 million for Q1 2026.

  • For Q1 2026, Share-based Compensation fell 50.71% year-over-year to $3.2 million; the TTM value through Mar 2026 reached $17.4 million, down 71.38%, while the annual FY2025 figure was $20.7 million, 69.2% down from the prior year.
  • Share-based Compensation for Q1 2026 was $3.2 million at Zentalis Pharmaceuticals, up from $3.1 million in the prior quarter.
  • Over five years, Share-based Compensation peaked at $31.4 million in Q4 2024 and troughed at $3.1 million in Q4 2025.
  • A 5-year average of $11.3 million and a median of $10.4 million in 2024 define the central range for Share-based Compensation.
  • Biggest five-year swings in Share-based Compensation: soared 125.96% in 2024 and later crashed 90.05% in 2025.
  • Year by year, Share-based Compensation stood at $9.6 million in 2022, then soared by 44.4% to $13.9 million in 2023, then soared by 125.96% to $31.4 million in 2024, then crashed by 90.05% to $3.1 million in 2025, then rose by 2.4% to $3.2 million in 2026.
  • Business Quant data shows Share-based Compensation for ZNTL at $3.2 million in Q1 2026, $3.1 million in Q4 2025, and $4.8 million in Q3 2025.